The GLP-1 shortages are over. What happens next?
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
Drug Delivery Business3h
Vivani reports first human GLP-1 implant for weight loss in adults
Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...
New ‘natural’ GLP-1 booster that can be added to any food for weight loss to hit shelves within the next year
NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...
JD Supra5h
GLP-1 Receptor Agonists and Patent Strategy: Securing Patent Protection for New Use of Old Drugs
GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
Vivani Medical announces 1st GLP-1 implant in Liberate-1 clinical trial
Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...
The Ozempic workout? How gyms and trainers are catering to a new group of exercisers
With GLP-1 weight loss comes muscle loss. Gyms and personal trainers are rising to the challenge to help people build it back ...
BioWorld5d
MASH field still hot as Boehringer axes $870M deal with Yuhan
Boehringer Ingelheim GmbH terminated its second metabolic dysfunction-associated steatohepatitis (MASH) alliance on March 6, ending an $870 million license agreement inked with Yuhan Corp. for dual ...
BioSpace6d
Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II
Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with ...
Investing14d
Earnings call transcript: Altimmune Q4 2024 sees stock surge 7.41%
R&D expenses: $82.2 million in 2024, up from $65.8 million in 2023. G&A expenses: $21 million in 2024, up from $18.1 million in 2023. Net loss: $95 million in 2024, compared to $88 million in 2023.